INCY vs. UHS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at INCY and UHS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | INCY | UHS |
|---|---|---|
| Company Name | Incyte Corporation | Universal Health Services, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 20.60 billion USD | 14.57 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | November 4, 1993 | July 9, 1981 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of INCY and UHS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| 5-Day Price Return | -1.73% | 1.08% |
| 13-Week Price Return | 19.82% | 26.09% |
| 26-Week Price Return | 71.27% | 17.10% |
| 52-Week Price Return | 29.41% | 10.99% |
| Month-to-Date Return | 11.41% | 3.70% |
| Year-to-Date Return | 50.79% | 25.43% |
| 10-Day Avg. Volume | 2.75M | 0.61M |
| 3-Month Avg. Volume | 1.98M | 0.75M |
| 3-Month Volatility | 28.34% | 23.44% |
| Beta | 0.80 | 1.28 |
Profitability
Return on Equity (TTM)
INCY
29.83%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 29.83% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
UHS
19.89%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
In the upper quartile for the Health Care Providers & Services industry, UHS’s Return on Equity of 19.89% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
INCY
24.69%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
A Net Profit Margin of 24.69% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
UHS
8.09%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
A Net Profit Margin of 8.09% places UHS in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
INCY
30.76%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 30.76% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
UHS
11.47%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
An Operating Profit Margin of 11.47% places UHS in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Return on Equity (TTM) | 29.83% | 19.89% |
| Return on Assets (TTM) | 20.37% | 9.22% |
| Net Profit Margin (TTM) | 24.69% | 8.09% |
| Operating Profit Margin (TTM) | 30.76% | 11.47% |
| Gross Profit Margin (TTM) | 93.47% | -- |
Financial Strength
Current Ratio (MRQ)
INCY
3.20
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
INCY’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
UHS
1.03
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
UHS’s Current Ratio of 1.03 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
INCY
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
UHS
0.65
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
UHS’s Debt-to-Equity Ratio of 0.65 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
UHS
9.05
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
UHS’s Interest Coverage Ratio of 9.05 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Current Ratio (MRQ) | 3.20 | 1.03 |
| Quick Ratio (MRQ) | 2.86 | 0.96 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.65 |
| Interest Coverage Ratio (TTM) | 6.86 | 9.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
UHS
0.36%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Yield of 0.36% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
UHS
3.78%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Payout Ratio of 3.78% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.36% |
| Dividend Payout Ratio (TTM) | 0.00% | 3.78% |
Valuation
Price-to-Earnings Ratio (TTM)
INCY
17.49
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
INCY’s P/E Ratio of 17.49 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
UHS
10.54
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
In the lower quartile for the Health Care Providers & Services industry, UHS’s P/E Ratio of 10.54 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
INCY
4.32
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 4.32 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
UHS
0.85
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
UHS’s P/S Ratio of 0.85 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
INCY
3.56
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
INCY’s P/B Ratio of 3.56 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
UHS
1.81
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
UHS’s P/B Ratio of 1.81 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 17.49 | 10.54 |
| Price-to-Sales Ratio (TTM) | 4.32 | 0.85 |
| Price-to-Book Ratio (MRQ) | 3.56 | 1.81 |
| Price-to-Free Cash Flow Ratio (TTM) | 17.37 | 14.97 |